Total raised
—
Last: Seed 2015-01
Stage
Seed
Founded
2015
Headcount
6
HQ
Haifa
Sector
Health Tech & Life Sciences
About
MemoDero is developing a first-in-class drug candidate to prevent debilitating consequences of fear-related diseases, such as post-traumatic stress disorder. The company's team is currently in the advanced stages of developing and evaluating the drug pep-EphrinA4, aimed at reducing or preventing the debilitating consequences of fearful memories. The drug is intended to inhibit the development of a fear memory following a traumatic event.
Funding history · 1 round · — total
2015-01
Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
pharmaceuticalspatent-pendingmental-healthpharma-companiespatients